Enclomiphene Did Everything the Trials Asked. It Still Is Not an Approved Drug.
Almost every men's health telehealth company now sells enclomiphene, usually positioned as the smart alternative to testosterone replacement. The pitch is short and it is largely accurate: it raises your testosterone by making your own body produce more of it, rather than shutting your own production down and pouring the hormone in from outside. Fertility survives. Your testicles keep working. There is no gel to rub on and no needle. What the pitch tends to leave out is that enclomiphene is not an approved drug in the United States, and that this is not because nobody tried. A company ran the trials, hit the endpoints it set, filed with the FDA, and received a complete response letter in November 2015. It never came back. A decade later the compound is more widely used than it ever would have been as an approved product, distributed through a channel that involves no label, no package insert and no post-marketing surveillance. That gap between the evidence and the regulatory status is the actual story here, and it is more interesting than either the marketing or the dismissal. This article is educational background on an unapproved drug. It is not medical advice, a protocol or a recommendation.
It Is Half of a Drug That Has Been Around Since 1967
Clomiphene citrate was approved for female infertility in 1967 and has been prescribed off label to men for decades. It is not one molecule. It is a mixture of two geometric isomers that behave differently in the body, and the ratio is roughly 38 percent enclomiphene to 62 percent zuclomiphene. Enclomiphene is the trans isomer and it is the anti-estrogenic half, the part that blocks estrogen receptors at the hypothalamus and pituitary. Zuclomiphene is the cis isomer and it is weakly estrogenic, which is the opposite of what you want if the goal is to lift the brake off the gonadal axis. The half lives are the part that gets under-explained. Enclomiphene clears in a matter of days. Zuclomiphene has an elimination half life measured in weeks, so on daily dosing it accumulates, and a man taking clomiphene for six months is carrying around a slowly building reservoir of the estrogenic isomer. The argument for enclomiphene as a separate product is that you can keep the useful half and discard the one that works against you. That is a clean pharmacological argument. Whether it produces a clinically different experience is a separate question, and the human evidence for it is thinner than the argument itself.
The Isomer Argument, Measured Once
Rate of adverse effects in a retrospective cohort of 66 men treated for a median of 8.9 months, cited in the 2026 BSSM statement. Clomiphene contains both isomers, including the estrogenic one that accumulates over weeks. Enclomiphene is only the anti-estrogenic isomer. This is the clearest human comparison behind the claim that separating them matters, and it is retrospective, single-cohort and unblinded, which is exactly as much weight as it can carry.
- Adverse effect rate (%)
Why Adding Testosterone Turns Your Own Off
The hypothalamic pituitary gonadal axis runs on negative feedback. The hypothalamus releases GnRH in pulses, the pituitary answers with luteinizing hormone and follicle stimulating hormone, LH tells the Leydig cells in the testes to make testosterone, and FSH supports the Sertoli cells that sustain sperm production. Circulating testosterone and the estradiol it gets converted into then travel back to the hypothalamus and pituitary and tell them to ease off. Introduce testosterone from outside the body and that feedback fires exactly as designed. LH and FSH fall, often to nearly nothing, and the testes stop being asked to do anything. Testosterone in the blood is now normal or high while intratesticular testosterone, which sits at concentrations far above serum levels and is what spermatogenesis actually depends on, collapses. This is why sperm counts drop on testosterone replacement, why testicular volume decreases, and why a meaningful number of men on long-term therapy become azoospermic. It is not a side effect in the sense of an unpredictable reaction. It is the mechanism working correctly. Enclomiphene attacks the problem from the other end. By blocking estrogen receptors centrally it makes the brain read estrogen as low, so the brake comes off, LH and FSH rise, and the testes are told to work harder. Everything downstream stays connected.
The Phase III Trials Did What They Were Designed to Do
Two parallel phase III studies, ZA-304 and ZA-305, tested enclomiphene against testosterone gel and placebo in overweight men aged 18 to 60 with secondary hypogonadism. Entry required a morning total testosterone at or below 300 ng/dL on two separate measurements taken a few days apart, along with an LH that was low or normal, which is what distinguishes a signaling problem upstream from testicular failure. Mean baseline testosterone was around 205 ng/dL. On enclomiphene it rose to 446 ng/dL in one study and 413 ng/dL in the other, comfortably inside the normal range. LH and FSH rose alongside it, which is the fingerprint of stimulation rather than replacement, and is the specific result you would never see on a gel. The sperm data is where the two drugs separated. Sperm concentration rose 12 to 15 percent on enclomiphene. On testosterone gel it fell by somewhere between a third and more than half. A urologist looking at those two columns is looking at the entire clinical case for the drug, and it is a real case. The trials were not ambiguous and the effect was not marginal.
The Hormone Endpoint Was Never in Doubt
Mean total testosterone in the two parallel phase III studies, ZA-304 and ZA-305, in overweight men with secondary hypogonadism. Both started around 205 ng/dL, which is below the threshold most labs use to define a low reading, and both landed in the normal range on enclomiphene. Neither trial had trouble hitting this. What happened afterward had almost nothing to do with these bars.
Then the FDA Said No, and the Reasons Were Not About Efficacy
In October 2015 the FDA cancelled an advisory committee meeting that had been scheduled for November to review the enclomiphene application, citing questions about bioanalytical method validation that could affect how the pivotal study data were interpreted. A complete response letter followed on 30 November 2015. Repros Therapeutics, the sponsor, met with the FDA's Division of Bone, Reproductive and Urologic Products in February 2016 to work through it, and simultaneously announced it would pursue a European filing instead. Several threads were tangled together. There were assay and manufacturing questions specific to this application. There was also a much larger problem the drug had walked into, which was that in 2015 the FDA had just required every approved testosterone product to carry new labeling about possible cardiovascular risk, and the agency was in no mood to approve a new drug for raising testosterone on the strength of hormone levels alone. The question shifted from whether the number moves to whether moving the number helps the patient, and that is a question the program was not designed to answer. Repros never got a resubmission across the line. The company was eventually acquired, no successor filed again, and enclomiphene has never been approved in the United States. Notice what did not happen. No trial found the drug ineffective. No safety signal killed it. A small company ran out of runway in front of a moving regulatory target.
The Endpoint That Separated the Two Drugs
Change in sperm concentration across the phase III program. Testosterone gel dropped sperm concentration by roughly a third to more than half, which is the expected consequence of shutting down the signal from the pituitary. Enclomiphene raised it slightly. The ranges shown are the low and high estimates reported across the two studies, not a confidence interval.
What Pooling a Decade of Trials Shows
A systematic review and meta-analysis published in Archives of Endocrinology and Metabolism in October 2025 gathered the randomized controlled trials of clomiphene and enclomiphene in men with functional hypogonadism, searching through July 2024 and finding ten trials covering 819 patients. Against placebo, total testosterone rose 273.76 ng/dL with a confidence interval running from 191.87 to 355.66. LH rose 4.66 IU/L and FSH rose 4.59 IU/L, both with intervals well clear of zero. The comparison that deserves more attention is the one against testosterone gel, where the analysis found no significant difference in total testosterone. An oral drug that leaves the axis intact reaches the same serum number as the gel. That is the strongest single sentence anyone can say in favor of this class, and it comes from pooled randomized data rather than from a clinic's marketing page. The limits are equally clear. The analysis pools clomiphene and enclomiphene together, which blurs the isomer question that the whole product concept rests on. The trials are short. And a mean difference in a hormone concentration is a laboratory result, not a report of how a man feels at week fifty.
What Ten Randomized Trials Say About the Signal Upstream
Pooled mean difference against placebo for luteinizing hormone and follicle stimulating hormone, from a 2025 systematic review of ten randomized controlled trials covering 819 men treated with clomiphene or enclomiphene. Each hormone is shown as the lower bound of the 95 percent confidence interval, the point estimate, and the upper bound. Both intervals sit well clear of zero. That both gonadotropins rise is the mechanistic difference between stimulating the axis and replacing its output, and it is the one thing exogenous testosterone can never do. Total testosterone in the same analysis rose 273.76 ng/dL against placebo.
- 95% CI lower bound
- Mean difference
- 95% CI upper bound
The Symptom Question Nobody Has Really Answered
Here is the uncomfortable part of the evidence base, and it applies to testosterone therapy generally rather than to this drug specifically. The endpoints in these trials are overwhelmingly biochemical. Total testosterone, LH, FSH, sperm concentration. Those are easy to measure, they move reliably, and they make for clean charts. The reasons men actually seek treatment are fatigue, low libido, poor erections, low mood, difficulty holding muscle and a general sense that something has drifted. Those are harder to measure, they respond substantially to placebo, and they are much less consistently reported in the enclomiphene literature. There are trials that looked, and there are signals, but nothing in this file is the equivalent of a large, long, well-powered trial showing that men on enclomiphene feel and function better than men on placebo across a year. The 2025 meta-analysis notes the same shape of gap. Anyone deciding what to do with this information should be clear about which question the evidence answers. It answers, robustly, whether the drug raises testosterone while preserving fertility. It does not yet answer, with the same confidence, whether a man with a total testosterone of 260 and vague symptoms will be better off in twelve months for having taken it.
A Specialist Society Looked at This in July 2026
The British Society for Sexual Medicine published a position statement on enclomiphene in the World Journal of Men's Health on 1 July 2026, and it is the most useful single document for anyone trying to place this drug. The society describes enclomiphene as a promising oral therapy for men with secondary hypogonadism, particularly those who want to preserve fertility or who cannot tolerate injections and transdermal preparations. It then constrains that considerably. Because long-term efficacy and safety data do not exist, and because the drug is unlicensed in the United Kingdom, the BSSM advises that use be limited to experienced clinicians in specialist or research settings with proper patient counselling. The evidence it summarizes is modest in scale. A randomized trial of 44 participants found post-treatment testosterone non-inferior to transdermal testosterone at both 24 hours and six weeks across doses from 6.25 to 25 mg daily. One retrospective cohort of 66 patients treated for a median of 8.9 months reported a median testosterone rise of 5.76 nmol/L with adverse effects in 13.8 percent, against 47 percent for clomiphene. A second retrospective analysis of 78 patients found no statistically significant differences in testosterone, LH, FSH or semen parameters at all. The dosing discussed starts at 6.25 mg daily and titrates weekly toward 25 mg, with escalation to 50 mg where response is inadequate. Reported side effects are mild and uncommon: headache at 1.6 percent, hot flushes at 1.1 percent, nausea at 1.0 percent, muscle spasms at 0.9 percent, dizziness at 0.7 percent. Read the two retrospective studies against each other and you have an accurate picture of the field. One found a clear benefit, one found nothing, and neither was designed in a way that settles the disagreement.
Reported Side Effects Are Uncommon and Unremarkable
Adverse event rates cited in the British Society for Sexual Medicine position statement published in July 2026. Nothing here is alarming, and tolerability has never been the argument against this drug. The gap in the file is duration. These figures come from short studies, and the questions that matter for a daily oral hormone therapy, meaning bone, cardiovascular and prostate outcomes over years, are not answered by them.
How an Unapproved Drug Became a Retail Product
The regulatory path enclomiphene actually travels is compounding. Under section 503A of the Food, Drug and Cosmetic Act a pharmacy can compound a preparation for an individual patient with a valid prescription, and one route to doing that legally is for the active ingredient to appear on the FDA's list of bulk drug substances approved for that use. Enclomiphene citrate was nominated for that list. On 8 June 2022 the Pharmacy Compounding Advisory Committee reviewed it and voted against inclusion, aligning with the FDA's own proposal that it not be added. That recommendation is advisory, and the substance has continued to sit in the category of nominations still under evaluation, a status that in practice has allowed compounding to continue while the agency works through a long backlog. That is the entire legal foundation of a product category now measured in the hundreds of millions of dollars, with men's health clinics accounting for a large share of it. It is worth being plain about what this means for a buyer. A compounded preparation has no FDA-approved label, no package insert, no approved indication and no manufacturer conducting post-marketing safety surveillance. Quality depends on the individual pharmacy, and compounded products are not required to demonstrate bioequivalence to anything, because there is no approved reference product to be equivalent to. None of that makes compounded enclomiphene bad. It makes it unverified in ways that an approved drug is not, and the status could change if the FDA finalizes the list.
What a Reasonable Reading Looks Like
Strip away both the marketing and the reflexive dismissal and a fairly clear position remains. Enclomiphene has a coherent mechanism, randomized evidence that it raises testosterone into the normal range, randomized evidence that it does so while preserving or slightly improving sperm concentration where testosterone gel sharply reduces it, and a short-term side effect profile that has never been the problem. It also has no FDA approval, no long-term outcome data on bone, cardiovascular or prostate endpoints, an unresolved question about how much of its symptomatic benefit is real, and a distribution channel that operates in a regulatory gap rather than through an approved product. Both halves of that are true at the same time, and the men most likely to be poorly served are the ones told only one of them. The category where the case is strongest is narrow and specific: a younger man with genuinely secondary hypogonadism, confirmed by repeat morning testing with low or normal LH, who wants to preserve fertility. That is the population the trials enrolled. Extending it to a man in his fifties with a mid-range testosterone level and general fatigue is an extrapolation the data does not support, and the first useful step there is a proper workup with a clinician rather than an intake form. This article is educational and describes an unapproved drug. It is not a protocol and not a recommendation to obtain or use anything.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Tribulus Is Sold as a Testosterone Booster. Eight of Ten Trials in Men Found No Change in Male Hormones, and the Erection Benefit It Does Show Arrives Without a Testosterone Rise.
Does tribulus raise testosterone? Eight of ten trials in men found no change. A 180-man trial did show better erections. What the research found, plus safety.
Three Beers a Night for Three Weeks Cut Testosterone by About 7 Percent. The Bigger Cost to Men Who Train Shows Up in the Muscle.
Does alcohol lower testosterone? In a diet-controlled trial, about 40 grams of alcohol a day for three weeks lowered testosterone in middle-aged men by 6.8 percent. Heavy drinking lowers it far more, and alcohol after training cut muscle protein synthesis by 24 to 37 percent. An educational review of the dose, the timing and what a month off actually changes.
16:8 Fasting Loses About the Same Weight as Counting Calories. The Early Window and the Muscle Question Are What Actually Differ.
In four randomized trials, an 8-hour eating window produced between 2.3 kg more and 0.8 kg less weight loss than its comparison diet. The 12-month NEJM trial found no significant edge over calorie restriction. An early 7 am to 3 pm window did better, and one trial in trained men saw testosterone fall. An educational review of the time-restricted eating evidence for men.